17-Jan-2025
No headlines found.
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
ACCESSWIRE (Mon, 16-Dec 8:51 AM ET)
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
ACCESSWIRE (Wed, 27-Nov 8:30 AM ET)
ACCESSWIRE (Wed, 20-Nov 8:30 AM ET)
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
ACCESSWIRE (Tue, 19-Nov 8:15 AM ET)
ACCESSWIRE (Thu, 31-Oct 8:58 AM ET)
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
ACCESSWIRE (Mon, 28-Oct 8:31 AM ET)
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Envveno Medical trades on the NASDAQ stock market under the symbol NVNO.
As of January 17, 2025, NVNO stock price climbed to $3.29 with 49,248 million shares trading.
NVNO has a market cap of $57.69 million. This is considered a Micro Cap stock.
In the last 3 years, NVNO traded as high as $7.93 and as low as $2.45.
The top ETF exchange traded funds that NVNO belongs to (by Net Assets): VTI, VXF, IWC, DFAT.
NVNO has underperformed the market in the last year with a price return of -18.4% while the SPY ETF gained +28.0%. NVNO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +0.3% and -2.1%, respectively, while the SPY returned +3.0% and +1.0%, respectively.
NVNO support price is $3.00 and resistance is $3.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVNO shares will trade within this expected range on the day.